While combination therapy with an immunomodulator and an anti-TNF medicine is beneficial for inflammatory bowel disease, it is not without hazards, such as infections and cancer. De-escalating to anti-TNF monotherapy by discontinuing the immunomodulator may provide advantages such as risk reduction and pharmaceutical regimen simplification for individuals in stable remission after one year. According to studies, discontinuing the immunomodulator rather than the anti-TNF medicine results in better outcomes, with recurrence rates being high after discontinuing anti-TNF therapy. Several recent trials discovered that quitting immunomodulators had no significant influence on outcomes if patients were initially in objective remission. While combination therapy may still be beneficial for certain individuals, experts advise making a shared choice based on unique patient characteristics.

To know more: About the original article click here.